Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Escape Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Tyrosine on Behavioral, Physiological and Nutritional Status During Survive, Evade, Resist, Escape (SERE) School

NCT01823276
View directory record Official record
Conditions
Response to Severe Stress
Interventions
Tyrosine-Containing Bar, Placebo Bar
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years · Male only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00264550
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab 100 mg, Golimumab 50 mg, Methotrexate, Placebo injection, Placebo capsules
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
13
States / cities
Mobile, Alabama • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

NCT01791153
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 19, 2026, 10:18 AM EDT
Recruiting Not applicable Interventional

Modulating Escape Using Focused Ultrasound

NCT06273904
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Active transcranial focused ultrasound (tFUS), Sham transcranial focused ultrasound (tFUS)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 19, 2026, 10:18 AM EDT
Recruiting Not applicable Interventional

Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression

NCT05011864
View directory record Official record
Conditions
Depression, Unipolar, Fall
Interventions
Behavioral Activation, Fall Prevention, Telephone support
Behavioral · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
50 Years to 100 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01172938
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 19, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
APG777
Drug
Lead sponsor
Apogee Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326298
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

NCT01009086
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Encinitas, California • La Jolla, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Response to Acute Exercise in Eating Disorders

NCT06213883
View directory record Official record
Conditions
Eating Disorders
Interventions
Biobehavioral Response to in-lab exposure to physical activity
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years to 25 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 4 Interventional

Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children

NCT02187952
View directory record Official record
Conditions
Pediatric Feeding Disorders
Interventions
Behavioral feeding intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
12 Months to 48 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Critical Smoke Alarm Characteristics to Awaken Children From Stage 4 Sleep

NCT01169155
View directory record Official record
Conditions
Smoke Inhalation Injury, Burns
Interventions
Smoke Alarm Stimuli
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 84 Years
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 19, 2026, 10:18 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT05911841
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LY3454738, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Fort Smith, Arkansas • North Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Resurgence as Choice: Basic and Clinical Studies

NCT03423940
View directory record Official record
Conditions
Problem Behavior, Self-injury, Communication
Interventions
Functional communication training
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
3 Years to 19 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

NCT01911065
View directory record Official record
Conditions
Herpes Zoster
Interventions
Zostavax™
Biological
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 4 Interventional

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

NCT03333655
View directory record Official record
Conditions
Neoplasms
Interventions
Biopsy
Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Not applicable Interventional

The Effectiveness of Immersive Virtual Reality as a Pain Control Modality After Hip Arthroscopy

NCT05868369
View directory record Official record
Conditions
Hip Pain Chronic
Interventions
iVR Group, Standard pain management regimen
Device · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

NCT01087762
View directory record Official record
Conditions
Spondyloarthropathies
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
32
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

NCT01077362
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
placebo, ustekinumab 45 mg, ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

NCT03747939
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Apremilast (CC-10004), Apremilast (CC-10004) Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Mesa, Arizona • Covina, California • Encino, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 10:18 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control

NCT02483572
View directory record Official record
Conditions
Aggression, Self-Injurious Behavior
Interventions
Functional Communication Training
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
3 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 19, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00361335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab, Methotrexate, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
20
States / cities
Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 19, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

Combination of TATE and PD-1 Inhibitor in Liver Cancer

NCT03259867
View directory record Official record
Conditions
Hepatocellular Carcinoma, Gastric Cancer
Interventions
Nivolumab Injectable Product, Trans-arterial tirapazamine embolization
Drug · Combination Product
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Orange, California • Oklahoma City, Oklahoma • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 19, 2026, 10:18 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Digitally Enhanced Smoking Cessation for High Risk Smokers

NCT04691297
View directory record Official record
Conditions
Smoking, Smoking Cessation, Lung Cancer Screening, Smoking, Tobacco, Smoking Behaviors
Interventions
Escape, Standard Care
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
55 Years to 77 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 19, 2026, 10:18 AM EDT